SNI Blog

SNI Blog

New center brings tertiary neurological care to children

Karen Pabillon

The Pediatric Epilepsy and Pediatric Neurology services at Swedish Medical Center have combined to create the new Swedish Pediatric Neuroscience Center. As part of the Swedish Neuroscience Institute (SNI), comprehensive neurological care for newborns, infants, children and adoles­cents is now located at the Swedish First Hill campus in Seattle. Marcio Sotero de Menezes, M.D., has been appointed direc­tor of the new center.

The center has a high patient volume for the medical and surgical treatment of seizure disorders, including complex epi­lepsy syndromes and genetic epilepsies. It is accredited by the National Association of Epilepsy Centers as a Level-4 epilepsy center.

In addition to epilepsy, the center’s specialists treat pediatric patients for a wide range of neurological disorders, in­cluding headache and migraine; move­ment disorders, tics and Tourette’s syn­drome; genetic and metabolic disorders; neurodevelopmental disorders and learn­ing disabilities; brain malformations; cere­bral palsy; stroke; tuberous sclerosis; and neurofibromatosis.

The center’s pa­tients will also benefit from a broad spectrum of pediatric neurol­ogy inpatient hospital services, including epilepsy monitoring unit, pediatric and neonatal intensive care units, procedural seda­tion services, pediatric neurosurgery and intraoperative EEG monitoring, imaging services, and neuropsychological testing. Physical, occupational and speech therapy services are also available to the center’s patients.

For more information about the Swedish Pediatric Neuroscience Center, please call 206-215-1440.

Exciting Advances in Multiple Sclerosis from ECTRIMS

Karen Pabillon

There is exciting news from last week’s 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

ALEMTUZUMAB. 5-year data from a Phase II extension study for alemtuzumab, an intravenously administered monoclonal antibody, showed that the drug:

  • reduced annualized rate of relapse to 0.14 compared with 0.28 for interferon
  • reduced the risk for sustained accumulation of disability in remitting relapsing multiple sclerosis by 87% compared to 62% with interferon.

This is a remarkable agent with excellent activity in MS. Adverse events included immune thrombocytopenic purpura, thyroiditis and anti-glomerular basement membrane disease.

TERIFLUNOMIDE. A Phase III trial of oral teriflunomide in remitting relapsing MS showed:

  • a 31% reduction in relapse rate and increased time to first relapse compared with placebo
  • reduced the risk of sustained disability progression by 29.8%.

Side effects were mild and included diarrhea, nausea, liver function abnormalities and hair loss.

Alemtuzumab and teriflunomide are currently in Phase III clinical trials at SNI.

SNI PRESENTATIONS:

  • Dr. Jim Bowen presented a poster about ongoing demyelination and neurodegeneration in a patient who had undergone autologous stem cell transplantation.
  • Drs. Jung Henson and Mayadev reviewed the beneficial effects of exercise on functional and quality of life outcomes from SNI’s MS wellness program

Clinical Neurophysiology Lab Receives Accreditation

Karen Pabillon

Congratulations are in order for the Clinical Neurophysiology Laboratory for attaining Accreditation by the EEG Laboratory Accreditation board of ABRET. We are the first and only Lab to receive Accreditation in Washington State and one of only 10 labs west of the Mississippi. Accreditation means the Lab has met strict standards and is recognized as a place where patients and physicians can have confidence they are receiving quality diagnostics. Thanks for all the great work and CONGRATULATIONS to everyone on the team who made this possible!

-Colleen Douville

Director for Cerebrovascular Ultrasound
Program Manager for Clinical Neurophysiology

The neurophysiology laboratory at Swedish is a critical component to the Epilepsy program.

Staying Fit to Prevent Stroke

William H. Likosky

A brisk walk for as little as 30 minutes a day can improve your health in many ways and may reduce your risk for stroke. Join me, and one of our exercise physiologists to learn how to stay fit and reduce your risk for stroke. Free blood pressure screening will also be available.

Cherry Hill - Pinard Foyer

Tuesday, Oct. 12, 11 a.m.-1 p.m

For more information, please contact Sherene Schlegel:

sherene.schlegel@swedish.org

Office: 206-320-3484

SNI Fellowship Opportunities Available

Karen Pabillon

The Swedish Neuroscience Institute (SNI) at Swedish Medical Center in Seattle, Washington, is committed to improving the delivery of neurologic care through evidence-based protocols, research and education. SNI offers advanced training through five fellowships:

Applications are reviewed as received, with fellowships beginning bi-annually on January 1 and July 1. For one hundred years Swedish has been the premier health-care provider in the Pacific Northwest and a trusted resource for people when it truly counts. As a high-volume, urban medical center located at the epicenter of the Puget Sound area, Swedish attracts nationally recognized physicians and scientists, and provides a broad population base that enhances the patient care, research and education efforts at SNI. Applying for an SNI fellowship You can also email your inquiries to SNIFellowships@swedish.org

Hot off the press! Summer 2010 BrainWaves available

Karen Pabillon

The Summer 2010 Edition of BrainWaves is now available online.

BrainWaves is the newsletter of the Swedish Neuroscience Institute. Published quarterly, BrainWaves provides information about neurological conditions treated at the Institute, and also profiles the programs, services, and new initiatives of the institute and its staff.

Also check out our past editions of the BrainWaves newsletter.

Gamma Knife Radiosurgery for Treatment of Essential Tremor

Ronald F. Young, MD

Essential tremor (ET) is the most common type of movement disorder, affecting approximate­ly four out of 1000 people, and is significantly more common, though less recognized, than Parkinson’s disease. ET affects men and women equally and is inherited as an autosomal-dominant condition in about 60 percent of cases.

Although often referred to as benign essen­tial tremor, it is hardly benign in patients who may not be able to write legibly, hold a glass of water or use a knife and fork. ET is primarily an action tremor of the upper extremities but may involve resting tremor of the head and neck and/or lower jaw, and also tremor of the voice. The latter may be so severe that speech becomes unintelligible.

Medication and surgical treatment options

Primidone and beta blockers are useful in re­ducing tremor in the early stages of ET, but as the tremor progresses, medical management often becomes less effective or side effects can prevent the use of adequate doses of medication. ET pa­tients then are candidates for surgical or radiosur­gical treatment.

The mainstay of the surgical treatment of ET is deep brain stimulation (DBS), in which an electrode is implanted in the ventral inter­mediate nucleus (VIM) of the thalamus. Neurosurgeons Peter Nora, M.D., and Ryder Gwinn, M.D., have been implant­ing DBS electrodes at Swedish Medical Center for several years. The treatment is effective, but it requires implantation of permanent hardware (wires and batteries) into the brain and chest wall. Patients who take anticoagulants or have severe cardio­vascular disease are not suitable candidates for DBS. These patients, however, may be candidates for radiosurgical treatment.

A new option for difficult-to-treat patients

Results 57-63 of 70

Top Authors

Karen Pabillon
Peggy Shortt, MN, ARNP

Peggy Shortt, MN, ARNP
Manager, Swedish Deep Brain Stimulation Program

John W Henson IV

John W Henson IV
Director, Neurology

Erin Kieper

Erin Kieper
Program Development Manager, Swedish Radiosurgery Center